An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

Recent reports have now implicated interleukin 12 and interleukin 23 ... The human monoclonal antibody ustekinumab blocks the biologic activity of IL-12 and IL-23 by inhibiting receptors of ...

J&J’s pharma unit Janssen said Stelara is the first interleukin-12/23 inhibitor to be approved for UC, an inflammatory bowel disease which affects around 2.6 million people in Europe.

Celltrion, a leading Korean biotechnology firm, has successfully developed Zymfentra, a subcutaneous version of the company’s ...

Meanwhile, Janssen’s Stelara is set to become the highest-grossing interleukin inhibitor in the market. Stelara is predicted to be the ninth best-selling drug in the world by 2025.

Insufficient documentation in regard to fetal safety implies the discontinuation of leflunomide, tofacitinib as well as abatacept, rituximab, belimumab, tocilizumab, ustekinumab and ... rituximab and ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term comparable efficacy and safety up to week 52. Patients with psoriasis who switched ...

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...